Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. [PDF]
, 2014 Understanding genetic aberrations in cancer leads to discovery of new targets for cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not been fully described. Therefore, patients with refractory advanced/metastatic HCC referred
Janku, Filip +4 more
core +3 more sources
From obesity resistance to obesity prediction and prevention? [PDF]
, 2016 Comment on: Regulation of hypothalamic neuropeptides gene expression in diet induced obesity resistant rats: possible targets for obesity prediction?
Cassano, Tommaso, Gaetani, Silvana
core +4 more sources
Biology of advanced uveal melanoma and next steps for clinical therapeutics [PDF]
, 2014 Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes.
Bastian, BC +17 more
core +1 more source
HDAC inhibitors as anti‐inflammatory agents [PDF]
British Journal of Pharmacology, 2007 Diverse cellular functions including the regulation of inflammatory gene expression, DNA repair and cell proliferation are regulated by changes in the acetylation status of histones and non‐histone proteins. Many human diseases, particularly cancer, have been associated with altered patterns of histone acetylation.
openaire +2 more sources
The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma [PDF]
, 2018 Background: The use of alkylating agents such as temozolomide in association with radiotherapy (RT) is the therapeutic standard of glioblastoma (GBM).
Chen, Yi +12 more
core +2 more sources
The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma [PDF]
, 2008 We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's ...
Andrew Evens +9 more
core +1 more source
Improving Insulin Sensitivity With HDAC Inhibitor [PDF]
Diabetes, 2013 Histone deacetylase (HDAC) has emerged as a new molecular target in the control of obesity and type 2 diabetes. HDAC is an enzyme with well-known functions in the regulation of chromatin structure and gene transcription in the nucleus, where HDAC interacts with corepressor proteins such as NcoR and SMRT to form active corepressor complexes.
openaire +2 more sources
HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers [PDF]
, 2006 Valproic acid (VPA), a histone deacetylase inhibitor, causes differentiation in different cell lines and in a cell-specific manner; yet, its effect on megakaryocytic (MK) differentiation has not been studied.
Ciccarelli, Carmela +9 more
core
Communications BiologyKMT2A-rearranged acute lymphoblastic leukemia (ALL) is characterized by deregulation of the epigenome and shows susceptibility towards histone deacetylase (HDAC) inhibition.
Tamara C. A. I. Verbeek +7 more
doaj +1 more source
Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides
Case Reports in Medicine, 2010 Histone deacetylase (HDAC) inhibitors have shown significant activity in the treatment of cutaneous T-cell lymphomas (CTCL). The epigenetic alterations of CTCL not only are limited to altered histone acetylation but also include aberrant DNA gene ...
Alfonso Dueñas-Gonzalez +4 more
doaj +1 more source